Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2006

View Archived Issues

GRIMs: Novel cytokine-driven tumor suppressors

Anticoagulant proteins potentially useful for pneumonia and ARDS

Antigenics rounds up Q2 developments

Eisai reviews highlights of quarter

Antiallodynic effects of NAALADase inhibition in an in vivo model of neuropathic pain

IL-22: a novel target for autoimmune and inflammatory diseases

HIF-1alpha inhibition enhances antitumor activity of temozolomide

Oncolys BioPharma cleared to begin U.S. clinical trials of telomelysin

U. of Pittsburgh awarded NIAID grant for avian flu vaccine

Antisoma to study AS-1409 in renal cancer and melanoma

Agreement to study AE-37 in prostate cancer in Europe

Pharmexa cleared to begin phase Ib study of HIV vaccine EP-1090

Enrollment open in pivotal study of pralatrexate for peripheral T-cell lymphoma

U.S. DHS certifies BioThrax as approved product for homeland security

Bionomics profiles lead programs

BioDiem signs CRADA with CDC to develop bird flu vaccine

Caprospinol shows favorable results in acute toxicity study

Recent Cardiome patent describes new treatment options for cardiovascular disease

Chrysalin fails to meet primary endpoint in fracture repair

New agents for treating respiratory disorders reported in recent patent literature

Novel treatment options for inflammatory disorders disclosed in recent patents

Recent Synta patent describes novel immunosuppressant agents

German approval for Foster in asthma

Zensana NDA accepted for review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...